Skip to content

Discovery of novel cinnamic acid derivatives with anti-Helicobacter pylori mechanism.

Jul 2026 · Molecular diversity · 0 citations · 34 references
Medicine

TL;DR

Results suggested that compound 23 was a viable lead candidate for the treatment of Hp infection, and could cause severe cellular damage, disrupt biofilms, and inhibit urease, thereby blocking ammonia cloud formation.

View source

Similar papers

Open access Aug 2026

Exploring the anti-Helicobacter pylori activity of Guluchyadi Kashayam through in-vitro and in-silico analysis

The β-clamp protein is identified as a therapeutic target and CID 546,407 as a promising lead for drug development, driven by robust Van der Waals forces, which avoids the massive entropic penalties hindering other compounds.

Priya Venugopal, Abel Koshy, Anuroopa G. Nadh et al. · 0 citations
Review Sep 2026

Cinnamon-derived Phenylpropanoids against Candida: Multi-target Mechanisms and Medicinal Chemistry Perspectives.

Invasive candidiasis, particularly caused by drug-resistant strains, has emerged as a significant contributor to morbidity and mortality among hospitalized patients worldwide, posing a serious public health challenge. With the rising resistance to conventional antifungal agents such as azoles and echinocandins, the sea...

Zhao-Ling Shi, Jia-Jia Lin, Yang Xie et al. · 0 citations
Open access Sep 2026

Discovery of a Caffeic Acid Thioamide with Potent Activity against Pathogenic Fungi and Fluconazole Tolerance-Eliminating Effects in Candida albicans

Compound F4 emerges as a promising lead for antifungal drug development, distinguished by its broad‑spectrum activity, antibiofilm properties, and unique capacity to eliminate FLC tolerance.

Jia-Yin Wang, Qin-Li Guo, Nan Chen et al. · 0 citations
Sep 2026

Function-oriented synthesis of marine phidianidine derivatives as potent anti-MRSA agents.

Mechanistic study showed that 24a effectively inhibits biofilm formation and exerts its antibacterial effect by disrupting the bacterial cell membrane, paving the way for new strategies to combat antimicrobial resistance.

Qiong Wu, Bing-Yuan Yan, Chen Qu et al. · 0 citations
Open access Aug 2026

Development of isonicotinoyl-azole hybrids as potential InhA inhibitors for anti-tubercular activity.

The development of innovative treatment medicines that can overcome drug resistance and intracellular persistence is necessary since tuberculosis (TB) continues to be a significant worldwide health burden. In this work, series of hybrid compounds containing azole moieties, imine/semicarbazide linkers, and isonicotinoyl...

Wagdy M. Eldehna, Zainab M. Elsayed, M. Korycka-Machała et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.